Advertisement
Advertisement
-
Wuxi Biologics
TOPIC
 / company

Wuxi Biologics

Wuxi Biologics
Wuxi Biologics
Wuxi Biologics is a pharmaceutical research and services company based in Wuxi, Jiangsu province. It counts 16 of the world's top 20 drug makers as customers and 28 of China's 50 largest medicine producers. The company supplied ingredients for AstraZeneca's Covid-19 vaccine. It is one of six businesses founded by its chairman Ge Li, along with Wuxi Apptec.
Chairman / President
Li Ge
CEO / Managing Director
Chen Zhisheng
CFO / Finance Director
Tu Ming
Industry
Biopharmaceutical
Website
wuxibiologics.com.cn
Headquarters address
No. 108 Mashan Meiliang Road, Binhu Distroct, Wuxi City, Jiangsu Province, China
Stock Code
SEHK:2269
Year founded
2010
LATEST China Science NEWS

World-leading EV motor expert joins Hong Kong PolyU after 38 years in Britain

videocam
5
Zhu Ziqiang, who has joined Hong Kong Polytechnic University as chair professor of electrical machines and control systems. Photo: Handout

Nearly all advanced nations are part of a defence pact. Will China try to join?

videocam
13
Illustration: Lau Ka-kuen

Smells like popcorn: Chinese scientists’ gene-edited tomato offers aroma tweak

videocam
4
China produces more than a third of the world’s tomatoes. Photo: Shutterstock

Chen Mo – the man behind Heroes of Jin Yong – on AI and making a blockbuster game

videocam
A still from the upcoming martial arts title, Heroes of Jin Yong, which is on track to be the most expensive video game ever made in China. Photo: Handout

EU bans Chinese organisations from critical tech programmes, including AI, chips

videocam
64
The EU has barred most organisations based in China from applying for its Horizon Europe grants in “critical areas”. Image: Shutterstock
MORE China Science NEWS
WuXi Biologics credits the performance to its “follow and win the molecule” strategy, which aims to secure work across the full lifecycle of client drugs. Photo: Shutterstock
Hong Kong stock market

WuXi Biologics earnings jump as ‘follow and win the molecule’ strategy pays off

Chinese contract drug maker forecasts 46.3 per cent profit rise and signals continued growth despite US political scrutiny.

Hong Kong stock market

Hong Kong stocks rise as positive holiday bias sets in ahead of Lunar New Year

Banking & finance

Global funds, from BlackRock to Temasek, back China’s largest biotech firms

Hong Kong stock market

Hong Kong stocks climb as yuan strengthens and investors broaden focus beyond US

Hang Seng Index advances as investors shift focus, boosting Asian equities, with pharmaceutical and healthcare shares leading gainers.

The yuan hit its highest level since May 2023. Photo: Bloomberg
United States

Are Chinese biotechs what the doctor ordered as Big Pharma faces ‘patent cliff’?

US drug makers are racing to plug looming ‘patent cliff’ revenue gaps – and increasingly they are turning to China biotechs.

Science

Why US lawmakers killed a proposal targeting science efforts with China

US researchers and industry experts warn that even the revised version may have unintended consequences.

videocam
11
Advertisement
Advertisement
Advertisement
China manufacturing

China’s biotech firms may see ‘major breakthroughs’ within a decade. Here’s why

Strong manufacturing base a driving force behind overseas expansion, but industry leaders and analysts say hurdles remain.

videocam
Chinese biotech firms set to crack the global market within a decade, according to industry experts. Photo: Getty Images
Shanghai

China bets on bio-manufacturing as new growth engine, bid for tech self-reliance

The pilot-scale platforms are aimed at helping innovators overcome hurdles in R&D and manufacturing before achieving commercial production.

Hong Kong stock market

Ignore China’s innovation boom ‘at your own peril’, General Atlantic CEO warns

Easing of US-China tensions and strong Hong Kong equity market present new opportunities, William Ford says at the Family Business Summit.

Hong Kong stock market

Hong Kong stocks post longest decline in 9 months on renewed US-China tensions

Markets react to Trump’s threat to impose a 100 per cent tariff on all Chinese imports and restrict critical software exports from November.

The Hang Seng Index is headed for its steepest decline since a 13 per cent plunge on April 7. Photo: Jelly Tse
Biomedicine: Geopolitics

Trump’s tariffs on imported drugs ‘not a big concern’ for China’s pharma firms

Chinese drug makers have ‘minimal sales exposure to the US’, Jefferies analysts say.

The Trump administration’s new 100 per cent tariff on any branded or patented pharmaceutical product takes effect on October 1. Photo: Shutterstock
Hong Kong stock market

Hong Kong stocks cap weekly decline on valuation, tariff jitters

‘Gravity has reasserted itself’ and the global US$15 trillion rebound this year ‘now feels stretched’, investor says.

Hong Kong stock market

Chinese biotechs get a shot in the arm from policy support, licensing deals

‘We are on an upcycle in the industry and sentiment is very strong,’ Xufunds Investment fund manager Wang Chen says.

Biomedicine: Companies

Chinese biotech firm MGI’s DNA sequencers gaining in the market, BGI CEO says

MGI’s latest product, the DNBSEQ-T7+, can sequence 144 human genomes a day, or one every 10 minutes.

MGI Tech’s DNA sequencers offer the best “comprehensive value” in terms of time, quality and cost, according to BGI Group CEO Yin Ye. Photo: Shutterstock
Hong Kong stock market

Hong Kong stocks slip from 4-year high amid fears of US sanctions on drug makers

The Trump administration has been discussing severe restrictions on medicines from China, according to The New York Times.

Hong Kong stocks fell on Thursday. Photo: EPA
Hong Kong stock market

Alibaba surge leads Hong Kong stocks to biggest gain in 2 weeks

Hong Kong stocks are undervalued, and a ‘liquidity friendly environment’ is set to propel them higher, analyst says.

Hong Kong stock market

Hong Kong stocks rebound on US-China trade talk optimism

Hang Seng Index recovers from an intraday loss of as much as 0.9 per cent, snapping a four-day losing streak.

Advertisement
Advertisement
Advertisement
Hong Kong stock market

Hong Kong stocks sustain 3-year-high level on trade optimism

A US deal with Japan and scheduled talks with China reduce concerns about damage to the global economy from trade conflicts.

A crane lifts cargo from a container ship at the Port of Oakland in Oakland, California on July 14, 2025. Photo: EPA
Hong Kong stock market

Hong Kong stocks cap weekly gain on earnings optimism

Wuxi AppTec jumps after it says its first-half profit likely more than doubled from a year earlier.

Hong Kong stock market

Hong Kong stocks gyrate amid Iran conflict after US strike, Hormuz threat

Oil futures surge after US President Donald Trump says attacks ‘obliterated’ targets and Iran threatens to close key oil shipping route.

Hong Kong stock market

Hong Kong stocks rise on China policy hopes after soft economic data

China’s industrial output and fixed-asset investment fell short in May, and the downturn in the property market deepened.

Workers pack knives at a factory in Yangjiang, south China’s Guangdong province, on June 11, 2025. Photo: Xinhua
Hong Kong stock market

Hong Kong stocks erase gains amid ongoing US-China trade talks

Investors appear to look more cautiously at ongoing US-China trade talks in London.

Exchange Square in Central. Photo: Sam Tsang
Hong Kong stock market

Hong Kong stocks jump as US blocks Trump’s tariffs in win for global trade

Hang Seng Index approached a two-month high on bets global trade relations and market sentiment will improve.

videocam
Hong Kong stock market

Hong Kong stocks gain on earnings boost as Meituan beats market consensus

Gains limited by losses in leading carmakers amid lingering concerns about a prolonged price war.

videocam
Biomedicine: Companies

Big Chinese pharma can beat Trump’s policies with cost efficiencies: analysts

Trump seeks to slash domestic drug prices, bring back pharmaceutical manufacturing to the US and slap tariffs on imports.

videocam
A humanoid robot is shown delivering drugs at a mock pharmacy in Beijing in April 2025. Photo: EPA-EFE
China Future Tech briefing

Biomedicine | China’s biomedical sector braces for headwinds

The coast isn’t entirely clear for the world’s second-largest biomedical sector, which faces possible tariff increases and US import curbs.

***PLUS ONLY PLEASE DO NOT USE***
Biomedicine: Companies

China’s WuXi Biologics to sell Irish vaccine facility to Merck as US curbs loom

US passed Biosecure Act which would ban federal contracts with targeted firms and their business partners. Legislation explicitly names WuXi.

Biomedicine: Companies

WuXi AppTec, WuXi Biologics surge on slimmer chances of Biosecure Act’s passage

The bill’s absence from the proposed amendments to the US National Defence Authorisation Act comes as a reprieve for the two biotech firms.

Advertisement
Advertisement
Advertisement
Help preserve 120 years of quality journalism.
SUPPORT NOW
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement